Shopping Cart 0
Cart Subtotal
AED 0

Basilea Pharmaceutica Ltd (BSLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Basilea Pharmaceutica Ltd (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company's products address increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial infections and fungal infections, among others. Basilea also conducts research in the areas of anti-infectives, cancer and bacterial or fungal strains. It discovers drugs with the help of various technologies such as genomics, assay development, cell biology, and others. The company also operates in France, the UK, China, Germany, Spain, Switzerland, Italy and Denmark. Basilea is headquartered in Basel, Switzerland.

Basilea Pharmaceutica Ltd (BSLN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Basilea Pharma Enters into Agreement with Quintiles to Commercialize Zevtera 10

Basilea Pharmaceutica Plans To Enter Into Co-Marketing Agreement For Ceftobiprole 11

Licensing Agreements 12

Basilea Pharma Enters into Licensing Agreement with ArQule 12

Basilea Pharma Enters into Licensing Agreement with Shenzhen Gosun Pharma 13

Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 14

Pfizer Amends Licensing Agreement with Basilea Pharma 15

Avir Pharma Enters into Licensing Agreement with Basilea Pharma 16

Unimedic Pharma Enters into Licensing Agreement with Basilea Pharma 17

Equity Offering 18

Basilea Pharma Withdraws Public Offering of ADSs for up to USD189.5 Million 18

Debt Offering 20

Basilea Pharma Raises USD200.5 Million in Public Offering of 2.75% Bonds Due 2022 20

Basilea Pharmaceutica Ltd-Key Competitors 21

Basilea Pharmaceutica Ltd-Key Employees 22

Basilea Pharmaceutica Ltd-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 14, 2018: Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline 24

Feb 27, 2018: Basilea reports significantly improved financial results in 2017 28

Aug 10, 2017: Basilea reports improved financial results in half-year 2017 driven by growing product sales 31

Corporate Communications 34

Feb 21, 2018: Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors 34

Oct 31, 2017: Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor 35

Product News 36

11/02/2017: Basilea reports on commercial progress of antifungal Cresemba in Europe 36

10/23/2017: Strong Cresemba (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Basilea Pharmaceutica Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Basilea Pharma Enters into Agreement with Quintiles to Commercialize Zevtera 10

Basilea Pharmaceutica Plans To Enter Into Co-Marketing Agreement For Ceftobiprole 11

Basilea Pharma Enters into Licensing Agreement with ArQule 12

Basilea Pharma Enters into Licensing Agreement with Shenzhen Gosun Pharma 13

Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 14

Pfizer Amends Licensing Agreement with Basilea Pharma 15

Avir Pharma Enters into Licensing Agreement with Basilea Pharma 16

Unimedic Pharma Enters into Licensing Agreement with Basilea Pharma 17

Basilea Pharma Withdraws Public Offering of ADSs for up to USD189.5 Million 18

Basilea Pharma Raises USD200.5 Million in Public Offering of 2.75% Bonds Due 2022 20

Basilea Pharmaceutica Ltd, Key Competitors 21

Basilea Pharmaceutica Ltd, Key Employees 22

Basilea Pharmaceutica Ltd, Subsidiaries 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Basilea Pharmaceutica Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Basilea Pharmaceutica Ltd (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company's products address increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial infections and fungal infections, among others. Basilea also conducts research in the areas of anti-infectives, cancer and bacterial or fungal strains. It discovers drugs with the help of various technologies such as genomics, assay development, cell biology, and others. The company also operates in France, the UK, China, Germany, Spain, Switzerland, Italy and Denmark. Basilea is headquartered in Basel, Switzerland.

Basilea Pharmaceutica Ltd (BSLN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Basilea Pharma Enters into Agreement with Quintiles to Commercialize Zevtera 10

Basilea Pharmaceutica Plans To Enter Into Co-Marketing Agreement For Ceftobiprole 11

Licensing Agreements 12

Basilea Pharma Enters into Licensing Agreement with ArQule 12

Basilea Pharma Enters into Licensing Agreement with Shenzhen Gosun Pharma 13

Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 14

Pfizer Amends Licensing Agreement with Basilea Pharma 15

Avir Pharma Enters into Licensing Agreement with Basilea Pharma 16

Unimedic Pharma Enters into Licensing Agreement with Basilea Pharma 17

Equity Offering 18

Basilea Pharma Withdraws Public Offering of ADSs for up to USD189.5 Million 18

Debt Offering 20

Basilea Pharma Raises USD200.5 Million in Public Offering of 2.75% Bonds Due 2022 20

Basilea Pharmaceutica Ltd-Key Competitors 21

Basilea Pharmaceutica Ltd-Key Employees 22

Basilea Pharmaceutica Ltd-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 14, 2018: Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline 24

Feb 27, 2018: Basilea reports significantly improved financial results in 2017 28

Aug 10, 2017: Basilea reports improved financial results in half-year 2017 driven by growing product sales 31

Corporate Communications 34

Feb 21, 2018: Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors 34

Oct 31, 2017: Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor 35

Product News 36

11/02/2017: Basilea reports on commercial progress of antifungal Cresemba in Europe 36

10/23/2017: Strong Cresemba (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Basilea Pharmaceutica Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Basilea Pharmaceutica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Basilea Pharma Enters into Agreement with Quintiles to Commercialize Zevtera 10

Basilea Pharmaceutica Plans To Enter Into Co-Marketing Agreement For Ceftobiprole 11

Basilea Pharma Enters into Licensing Agreement with ArQule 12

Basilea Pharma Enters into Licensing Agreement with Shenzhen Gosun Pharma 13

Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 14

Pfizer Amends Licensing Agreement with Basilea Pharma 15

Avir Pharma Enters into Licensing Agreement with Basilea Pharma 16

Unimedic Pharma Enters into Licensing Agreement with Basilea Pharma 17

Basilea Pharma Withdraws Public Offering of ADSs for up to USD189.5 Million 18

Basilea Pharma Raises USD200.5 Million in Public Offering of 2.75% Bonds Due 2022 20

Basilea Pharmaceutica Ltd, Key Competitors 21

Basilea Pharmaceutica Ltd, Key Employees 22

Basilea Pharmaceutica Ltd, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Basilea Pharmaceutica Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.